C. Wheeler

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

B Romanowski, H. Kitchener, M. Lehtinen, 2009, The Lancet.

Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18

C. Wheeler, H. Kitchener, M. Lehtinen, 2012, International journal of cancer.

Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials

S. Wacholder, M. Sherman, M. Schiffman, 2018, The Journal of infectious diseases.

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.

C. Wheeler, F. X. Bosch, N. Muñoz, 2009, The Journal of infectious diseases.

Unrelatedness of factor VIII‐derived non‐A/non‐B hepatitis and hepatitis B virus

H. Margolis, C. Wheeler, D. Bradley, 1983, Journal of medical virology.